KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non-Current Liabilities: 2011-2024

Historic Other Non-Current Liabilities for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $47.3 million.

  • Supernus Pharmaceuticals' Other Non-Current Liabilities fell 75.63% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 75.63%. This contributed to the annual value of $47.3 million for FY2024, which is 11.43% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $47.3 million for FY2024, which was down 11.43% from $53.5 million recorded in FY2023.
  • Supernus Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $80.5 million during FY2021, with a 5-year trough of $45.8 million in FY2020.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $53.5 million (2023), whereas its average is $51.9 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Other Non-Current Liabilities spiked by 75.71% in 2021, and later slumped by 31.70% in 2022.
  • Over the past 5 years, Supernus Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $45.8 million in 2020, then spiked by 75.71% to $80.5 million in 2021, then plummeted by 31.70% to $55.0 million in 2022, then fell by 2.76% to $53.5 million in 2023, then decreased by 11.43% to $47.3 million in 2024.